Sellas Life Sciences Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.5
- Today's High:
- $1.57
- Open Price:
- $1.54
- 52W Low:
- $1.17
- 52W High:
- $5.58
- Prev. Close:
- $1.51
- Volume:
- 86374
Company Statistics
- Market Cap.:
- $42.52 million
- Book Value:
- 0.171
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $900000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -90.9%
- Return on Equity TTM:
- -301.93%
Company Profile
Sellas Life Sciences Group Inc had its IPO on 2017-12-29 under the ticker symbol SLS.
The company operates in the Healthcare sector and Biotechnology industry. Sellas Life Sciences Group Inc has a staff strength of 17 employees.
Stock update
Shares of Sellas Life Sciences Group Inc opened at $1.54 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.5 - $1.57, and closed at $1.51.
This is a 0% increase from the previous day's closing price.
A total volume of 86,374 shares were traded at the close of the day’s session.
In the last one week, shares of Sellas Life Sciences Group Inc have increased by +0.67%.
Sellas Life Sciences Group Inc's Key Ratios
Sellas Life Sciences Group Inc has a market cap of $42.52 million, indicating a price to book ratio of 3.7918 and a price to sales ratio of 47.7646.
In the last 12-months Sellas Life Sciences Group Inc’s revenue was $0 with a gross profit of $900000 and an EBITDA of $0. The EBITDA ratio measures Sellas Life Sciences Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sellas Life Sciences Group Inc’s operating margin was 0% while its return on assets stood at -90.9% with a return of equity of -301.93%.
In Q2, Sellas Life Sciences Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 82.5%.
Sellas Life Sciences Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sellas Life Sciences Group Inc’s profitability.
Sellas Life Sciences Group Inc stock is trading at a EV to sales ratio of 27.4527 and a EV to EBITDA ratio of -0.6222. Its price to sales ratio in the trailing 12-months stood at 47.7646.
Sellas Life Sciences Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.57 million
- Total Liabilities
- $13.42 million
- Operating Cash Flow
- $-2500000.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Sellas Life Sciences Group Inc ended 2024 with $18.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.57 million while shareholder equity stood at $4.84 million.
Sellas Life Sciences Group Inc ended 2024 with $0 in deferred long-term liabilities, $13.42 million in other current liabilities, 3000.00 in common stock, $-199841000.00 in retained earnings and $1.91 million in goodwill. Its cash balance stood at $13.81 million and cash and short-term investments were $13.81 million. The company’s total short-term debt was $447,000 while long-term debt stood at $0.
Sellas Life Sciences Group Inc’s total current assets stands at $15.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.73 million and inventory worth $0.
In 2024, Sellas Life Sciences Group Inc's operating cash flow was $-2500000.00 while its capital expenditure stood at $0.
Comparatively, Sellas Life Sciences Group Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.51
- 52-Week High
- $5.58
- 52-Week Low
- $1.17
- Analyst Target Price
- $6
Sellas Life Sciences Group Inc stock is currently trading at $1.51 per share. It touched a 52-week high of $5.58 and a 52-week low of $5.58. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $1.58 and 200-day moving average was $1.97 The short ratio stood at 9.22 indicating a short percent outstanding of 0%.
Around 20% of the company’s stock are held by insiders while 1803.9% are held by institutions.
Frequently Asked Questions About Sellas Life Sciences Group Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.